We provide the evidences towards improving the care of the patients.

Biostatistics Group

Faculty Member

  • Masahiko Gosho

    Masahiko GoshoProfessor

    Details of research achievement is here→TRIOS

    Primary research field is biostatistics for medical studies. In particular, I am trying to solve statistical issues arising in the process of the design, conduct, analysis, and evaluation of clinical trials of an investigational product. I am also developing novel statistical methods for analyzing longitudinal data and survival data.
    In the Tsukuba Clinical Research & Development Organization: T-CReDO, I am designing clinical trials, conducting data analysis, writing medical articles, and consulting on statistical issues in many medical fields as a trial statistician.

  • Kazushi Maruo

    Kazushi MaruoAssociate Professor

    Details of research achievement is here→TRIOS

    My main research field is statistics in clinical researches. Main thema is statistical analyses based on transformation models and evaluation for effect of parametric model misspecifications.
    In the Tsukuba Clinical Research & Development Organization: T-CReDO, I am designing clinical trials, conducting data analysis, writing medical articles, and consulting on statistical issues in many medical fields as a trial statistician.

Students

  • Ayako Sato

    Ayako Sato4th year PhD student

    I am interested in the design of clinical trials from my experience of drug development, and made it my research theme. My research is related to survey of clinical trials using adaptive design, and new design development.

    Publication List
    1. Sato A, Shimura M, Gosho M. Practical characteristics of adaptive design in phase 2 and 3 clinical trials. J Clin Pharm Ther. 2017 Aug 28. doi: 10.1111/jcpt.12617.
  • Masashi Shimura

    Masashi Shimura2nd year PhD student

    My research field is biostatistics. I am interested in developing a new statistical method for estimating exactly the effect of new drug in clinical trial. Exact estimation of the treatment effect compared to the standard treatment is important in terms of decision making in medicine. However, in clinical trials with interim analysis, it is well known that maximum likelihood estimator, which is used generally for estimation of the treatment effect, has bias. Through my statistical research for exact estimation of treatment effect in that situation, I would like to contribute something to clinical research.

    Publication List
    1. Shimura M, Gosho M, Hirakawa A. Comparison of conditional bias-adjusted estimators for interim analysis in clinical trials with survival data. Statistics in Medicine. 2017 Jun 15;36(13):2067-2080.
    2. Sato A, Shimura M, Gosho M. Practical characteristics of adaptive design in phase 2 and 3 clinical trials. Journal of Clinical Pharmacy and Therapeutics. 2017 Aug 28; in press.
    3. Takahashi M, Takahashi S, Araki N, Sugiura H, Ueda T, Yonemoto T, Morioka H, Hiraga H, Hiruma T, Kunisada T, Matsumine A, Shimura M, Kawai A. Efficacy of Trabectedin in Patients With Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II Studies. The Oncologist. 2017 May 18;22(8):979-988.
  • Ryota Ishii

    Ryota Ishii1st year PhD student

    My research field is biostatistics. My methodological research interests are in the areas of survival analysis and robust analysis. I am developing a new robust statistical method for the analysis of data with small-sample sizes in the framework of survival analysis. I have also worked at a pharmaceutical company and conducted many clinical trials as a biostatistician.

    Publication List
    1. Gosho, M., Maruo, K., Ishii, R., and Hirakawa, A. (2016). Analysis of an incomplete longitudinal composite variable using a marginalized random effects model and multiple imputation. Statistical Methods in Medical Research, doi: 10.1177/0962280216677879.
    2. Maruo, K., Tada, K., Ishii, R., and Gosho, M. (2017). An efficient procedure for calculating sample size through statistical simulations. Statistics in Biopharmaceutical Research, doi: 10.1080/19466315.2017.1349689

TOP